Core Viewpoint - Northstrive Biosciences Inc. is advancing its obesity treatment candidates, EL-22 and EL-32, focusing on fat loss while preserving muscle mass, with plans for regulatory meetings and clinical trials in 2025 [1][4][6]. Group 1: EL-22 Development - Northstrive is preparing for a Type B pre-IND meeting with the FDA in Q2 2025, having completed necessary translations and compiled data from its South Korean partner [2][3]. - EL-22 is a novel engineered probiotic targeting the myostatin pathway, showing significant improvements in preclinical studies and safety in a Phase 1 trial in South Korea [3][4]. - The company aims to file an Investigational New Drug application in 2025 to initiate clinical trials combining EL-22 with GLP-1 receptor agonists for obesity treatment [4][8]. Group 2: EL-32 Development - Northstrive has engaged a leading CRO for a preclinical study of EL-32, which expresses dual myostatin and activin-A inhibitors, focusing on glycemic control and body composition in diet-induced obese mice [5][8]. - The study will evaluate EL-32 both as a monotherapy and in combination with the GLP-1 receptor agonist semaglutide [5]. Group 3: Upcoming Presentation - Northstrive will present its obesity drug candidates at the UCLA Obesity Symposium on February 7, 2025, highlighting the muscle-preserving therapeutic potential of its myostatin-engineered probiotics [6]. Group 4: Company Overview - Northstrive Biosciences Inc. is a biopharmaceutical company under PMGC Holdings Inc., focusing on innovative treatments for obesity while preserving muscle mass during weight loss therapies [7][8].

Core Insights - PMGC Holdings Inc. has initiated strategic investments in fire prevention technology and the U.S. uranium energy market, highlighting its commitment to financing innovation in essential industries with significant growth potential [1][2] Investment Focus - The company believes there is a growing demand for sustainable energy solutions and innovative fire prevention technologies, with investments in uranium exploration supporting nuclear energy as a clean power source to reduce carbon emissions [2] - In the fire prevention sector, PMGC has invested in a U.S.-based company that is developing environmentally friendly technologies aimed at preventing fire ignition and spread, which could provide long-term solutions for saving lives and protecting real estate [3] Portfolio Management - PMGC is dedicated to keeping shareholders informed as its portfolio expands, with a commitment to report any individual investment that exceeds a 4.9% ownership threshold in compliance with SEC regulations [4] - PMGC Capital LLC operates as a multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets, aiming to identify high-potential opportunities for sustainable growth and maximizing returns [5] Company Overview - PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries, currently comprising three wholly owned subsidiaries [6]

Core Insights - PMGC Holdings Inc. announced a research agreement with a leading preclinical CRO to evaluate EL-32, a novel engineered probiotic, for its potential in treating obesity [1][4] - The study will assess EL-32's effects on glycemic control and body composition in diet-induced obese mice, both as a monotherapy and in combination with semaglutide [1][5] - EL-32 targets myostatin and activin-A pathways, aiming to preserve muscle mass while reducing fat mass, addressing a critical need in obesity treatment [2][4][3] Company Overview - Northstrive Biosciences Inc., a subsidiary of PMGC Holdings, focuses on developing innovative solutions for obesity treatment, particularly through engineered probiotics [7] - The lead candidate, EL-32, is designed to work alongside existing GLP-1 receptor agonists, which have been shown to cause significant muscle mass loss during weight loss [2][3][4] - PMGC Holdings operates a diversified portfolio, including Northstrive Biosciences, PMGC Research, and PMGC Capital, aiming to maximize growth across various sectors [9]

New York, New York, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the completion of the previously announced warrant inducement with existing institutional investors for its client PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the "Company" or "PMGC") (NASDAQ:ELAB), a diversified holding company, for the exercise of certain outstanding Series A warran ...

Warrant Inducement Agreement - PMGC Holdings Inc has entered into a warrant inducement agreement with existing institutional investors for the exercise of certain outstanding Series A warrants [1] - The investors agreed to exercise the outstanding warrants to purchase 969,385 shares of the company's common stock at an amended exercise price of $2 00 [1] - The gross proceeds from the exercise of the warrants are expected to be approximately $1 9 million [1] - The closing of the warrant inducement transactions is expected to occur on or about January 28, 2025 [2] New Warrants Issuance - In consideration for the exercise of the warrants, the company agreed to issue new warrants to purchase an aggregate of 969,385 shares of common stock with an exercise price of $2 75 per share [3] - The new warrants are exercisable upon shareholder approval and will expire five years from the date of shareholder approval [3] - The company has agreed to file a registration statement within 30 days with the SEC covering the resale of the shares issuable upon exercise of the new warrants [3] Company Overview - PMGC Holdings Inc is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries [5] - The company's portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc, PMGC Research Inc, and PMGC Capital LLC [5]

Northstrive Biosciences Inc. was invited to present EL-22, a novel myostatin asset aimed at preserving muscle while on weight loss treatments, at the UCLA Obesity Symposium called Anti-Obesity Treatments: Challenges and Emerging Solutions, organized by UCLA Metabolism Theme. This is an invite only event that brings together industry leading voices in the obesity space.NEWPORT BEACH, Calif., Jan. 24, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: EL ...

NEWPORT BEACH, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the "Company" or "PMGC") (NASDAQ:ELAB) a diversified holding company today announced the closing of the previously announced divestiture of its 100% wholly owned subsidiary Elevai Skincare Inc. ("Elevai") pursuant to a definitive purchase agreement with Carmell Corporation ("Carmell") (the "Divestiture") and reaffirms its commitment to accelerating shareholder value creation and market leadership followi ...

PMGC Research Inc., formerly Elevai Research Inc., is a development company focused on public-private collaborations leveraging research grants.Northstrive Biosciences Inc., formerly Elevai Biosciences, Inc., is a biopharmaceutical company targeting obesity with next-generation treatments. NEWPORT BEACH, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) is pleased to announce the renaming of its wholly owned subsidiaries as part ...

Divestiture Highlights Strategic Plans on Potential High-Impact Acquisitions Strategic Divestment Reduces Cash Burn and Enhances Operational Efficiency NEWPORT BEACH, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) today announced its commitment to accelerating shareholder value creation and market leadership following the sale of its skincare subsidiary, Elevai Skincare. This strategic divestiture marks a significant mileston ...

NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (NASDAQ:ELAB) (before and after the redomestication, the "Company" or "we") announced today that it completed a strategic reorganization. This reorganization included changing the Company's name from Elevai Labs Inc. to PMGC Holdings Inc. and redomiciling from Delaware to Nevada. Upon this reorganization, the Company will continue to trade on The Nasdaq Stock Market ("Nasdaq") under the ticker sy ...